The importance of providing clinical guidance that is based on the best available knowledge cannot be overstated; this task is one of the most crucial mandates of any medical organisation. The challenge has always been the changing nature of our understanding not only of medical treatments, of course, but also of what defines the best available knowledge. The first definitions outlining a potential “hierarchy” of knowledge were set down in 1979 [1] by a task force that included David Sackett, the “father” of evidence-based medicine ..read more

The authors regret that an error is displayed in Fig. 1 for the IO-VEGF and VEGF-TT overall survival curves which requires correction. The corrected figure is therefore displayed here. There is an accompanying change in the log rank p-value for IO-VEGF (p = 0.0003) associated with this correction. Finally, the 18-month OS benchmarks listed in the discussion for IO-VEGF should be corrected to 93%, 83%, and 74% for favorable, intermediate, and poor risk patients, respectively. These corrections do not change any trends or conclusions from the article ..read more

Non–muscle-invasive bladder cancer (NMIBC) is a very heterogeneous disease with a limited number of effective treatment options. Consensus among different societies regarding risk stratification is still lacking. For intermediate-risk (IR)-NMIBC, a recent consensus document aimed to shed some light on this grey zone [1]. Treatment protocols for IR-NMIBC recommend adjuvant instillation of a chemotherapy agent (mitomycin C [MMC] or gemcitabine) after transurethral resection of bladder tumor (TURBT ..read more

Lee HW, Lee HH, Park EY, et al ..read more

Mian BM, Singh Z, Carnes K, et al ..read more

We congratulate Gil-Jimenez et al. [1] on their validation of the effect of genomic biomarkers in predicting the response to cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer. The authors retrospectively collected data from multiple centers for 165 patients with muscle-invasive bladder cancer (MIBC) who received at least two cycles of cisplatin-based NAC before radical cystectomy. Tissue samples from transurethral resection before NAC were sequenced. For 9/68 (13%) responders and 2/95 (2%) nonresponders, somatic deleterious mutations in ERCC2 were observed (p = 0.009 ..read more

An updated version of Fig. 5 is shown below. The publisher regrets that the blue lines representing the anti-B7-H3 ADC treated arms were not visible in Fig. 5C–E, G–K in the initially published version ..read more

Abdel-Fattah M, Cooper D, Davidson T, et al ..read more

Groha S, Alaiwi SA, Xu W, et al ..read more

Kalyvianakis D, Mykoniatis I, Pyrgidis N, et al ..read more